Physician profile
James B Lim
NPI 1376934604
$428.83
in general payments reported to CMS, 2019-2025
11 companies · $188 in 2025
The $188 reported for 2025 was more than what 81% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.58 · 2020: $12.37 · 2021: $11.45 · 2022: $125 · 2023: $21.10 · 2024: $55.68 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $155.69 | 2022-2025 | |
| Revance Therapeutics, INC. | $40.76 | 2025 | Daxxify |
| Xeris Pharmaceuticals, INC. | $35.34 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $33.40 | 2025 | The Cologuard Plus Collection Kit |
| Alkermes, INC. | $33.33 | 2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $27.95 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $26.56 | 2025 | |
| Lilly USA, LLC | $22.91 | 2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $21.56 | 2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $19.88 | 2024 | Gattex |
| E.R. Squibb & Sons, L.L.C. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.